[Investor Alert] Planned Nasdaq Listing – WATCH THIS VIDEO
RJ Hamster
Editor’s Note: When we see offers from other publishers that might interest you, we pass them along. Below you’ll find one from our friends at Autonomix. Please note that their opinions may differ from what you read in Behind the Markets.
You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here.
For many, pain can be a constant in life, which is why painkillers are such a huge market – despite typically being a temporary (and sometimes dangerous) “band-aid” solution.
Autonomix has a better idea: Target pain at its source in the nervous system.
Alongside pain management, their breakthrough nerve-sensing technology has the potential to help treat a wide range of disorders including high blood pressure and digestive issues. It’s all with one tiny microchip that’s intended to target nerve signals at an accuracy never seen before.
The team has 100+ patents issued and pending, and with an estimated total of $100B+ in markets to address, we believe it’s a unique opportunity for investors.
(By clicking this link, you agree to receive future emails from Autonomix about company news and updates. You can opt out at any time. – Privacy Policy)
Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431
We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security.
We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of Autonominx. The compensation consists of up to $5,000 and was received/will be received from Strikepoint Media.
This compensation should not be considered as an endorsement of the securities of adviser Autonominx.and we are not responsible for any errors or omissions in any information provided about the securities of Autonominx..
We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions.
